12:00 AM
 | 
Sep 07, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Daxas roflumilast: Additional Phase III data

Additional data from 2 double-blind, international Phase III trials (EOS and HELIOS) showed that Daxas significantly improved mean pre-bronchodilator FEV1 by 49 mL in patients treated with Serevent salmeterol vs. placebo (p<0.0001) and by 80 mL in patients treated with Spiriva tiotropium vs. placebo (p<0.0001). Similar post-bronchodilator FEV1 was observed in both treatment groups. Nausea, diarrhea, weight loss and headache were more frequent in patients treated with Daxas vs. placebo. A total of 1,676 patients were administered 500 µg...

Read the full 383 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >